
Congressional Briefing Preparation for Medical Affairs
Convert clinical evidence into Congressional briefings and policy documents
What You Can Do
You can rapidly transform peer-reviewed clinical data, real-world evidence, and trial results into Congressional-grade policy documents that speak directly to legislative priorities—cost, access, public health, innovation, and safety. This skill enables you to respond to Congressional inquiries, assess legislative threats and opportunities, and develop evidence-backed advocacy positions without crossing into prohibited promotion or losing scientific credibility.
Features
converts complex medical findings into legislative language that stakeholders understand
ensures all briefings maintain scientific rigor and adhere to promotional guidelines and lobbying regulations
analyzes proposed healthcare bills and policy changes, extracting clinical and medical implications for executive briefing
distills evidence into concise, quotable advocacy language suitable for member offices and committee staff
organizes clinical evidence by strength (RCT, observational, real-world) to support specific policy positions
provides templates for responding to Congressional inquiries on drug class mechanisms, indication profiles, and public health issues
ensures all policy claims link back to peer-reviewed sources for transparency and regulatory defensibility
Example Output
Example 1: Congressional Inquiry Response
RE: SGLT2 Inhibitor Mechanisms for Diabetes Policy Hearing
SGLT2 inhibitors work by blocking glucose reabsorption in the proximal tubule, reducing A1C by 1.0–1.8% and independently lowering cardiovascular events and hospitalizations for heart failure in three Phase III RCTs (EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58). Key policy implication: evidence supports including this class in formulary coverage regardless of diabetes status, based on cardiovascular and renal protection in high-risk populations.
Evidence Hierarchy:
- RCT data: 14,000+ patients, 5+ years follow-up
- Real-world evidence: 2.3M patient-years (health system databases)
- Regulatory: FDA cardiovascular benefit labeling (2015–2021)
Example 2: Pricing Policy Position Paper (One-Pager)
Clinical Case for Orphan Disease Price Sustainability
Rare disease therapies require 10–15 years development and $500M+ investment with <50,000 U.S. patients. Proposed price controls limit manufacturer ability to fund: (1) post-market safety surveillance, (2) patient registries for long-term efficacy tracking, (3) supply chain resilience. Evidence: 3 therapies discontinued post-approval due to insufficient margin for safety monitoring (cite: FDA database, 2020–2023).
Policy Ask: Exclude orphan indications from proposed capitation model until real-world evidence on long-term outcomes matures (5+ years post-approval).
What's Included
- SKILL.md instruction file: complete framework for Congressional briefing preparation with use-case detection and compliance guardrails
- Congressional Inquiry Response Template: structured format for rapidly addressing member office and committee staff requests
- Position Paper Framework: outline for developing evidence-backed advocacy documents with evidence hierarchies and policy asks
- Regulatory Compliance Checklist: checklist for promotional guidelines, lobbying disclosure, and scientific substantiation requirements
- Talking Points Generator Prompt: template for distilling clinical data into quotable, legislative-ready language
- Threat/Opportunity Assessment Worksheet: structured analysis for evaluating proposed healthcare bills and policy changes against clinical/medical implications
Who It's For
- Medical Affairs Managers at pharmaceutical and biotech companies responding to Congressional inquiries and legislative requests
- Government Affairs and Regulatory Specialists developing legislative position papers and policy advocacy strategies
- Clinical Affairs Directors translating real-world evidence into healthcare policy arguments
- Compliance Officers and Legal Counsel reviewing briefing materials for regulatory adherence and promotional guideline compliance
- Chief Medical Officers briefing executives on clinical implications of proposed healthcare legislation
Best For
- Responding to Congressional staff inquiries on drug mechanisms, clinical benefits, and healthcare policy issues
- Developing legislative position papers that advance company healthcare policy positions
- Creating one-pagers and talking points for advocates and government affairs teams
- Assessing threats and opportunities posed by proposed healthcare bills
- Building evidence hierarchies and audit trails for regulatory defensibility







